Uveitis Treatment Market Share Analysis of The Top Industry Players, Growth Opportunities and Country Level Segments

Globally, North America is the largest, while Asia-Pacific is the fastest growing uveitis treatment market. The uveitis treatment market is witnessing significant growth, due to increasing prevalence of uveitis and related complications. The global uveitis treatment market currently has many technologically innovative products in the pipeline, which are expected to improve efficiency and safety profiles in the clinical trial stage of development, thereby reducing the progression of disease considerably. 

 

Anterior uveitis represents the largest growing segment of global uveitis treatment market, as per the type of uveitis. Anterior uveitis refers to redness in the middle layer of an eye, which contains ciliary body and iris. Anterior uveitis might be chronic or acute in nature. Anterior uveitis is caused primarily due to fungal, bacterial or viral infections and auto-immune disorders. The treatment for uveitis is primarily based on steroids and immunosuppressants. The global uveitis treatment market is currently dominated by uveitis treatment through corticosteroid (steroid medication) as well as off-label immuno-suppressive and biologic drugs.

Request to Get the Sample Pages at:

The global uveitis treatment market is witnessing substantial growth due to increased aging population, growing prevalence of uveitis and related complications. Moreover, introduction of innovative biologics, fast-track approval of pipeline drugs, increasing research and development investments in drug discovery and development, rising government initiatives to minimize eye disorders are also driving the growth of the global uveitis treatment market. Introduction of new routes for drug administration that improves the efficiency of the drug is another significant driver for uveitis treatment market. With the advancement of molecular biology, some intravitreal implants and biologic agents are increasingly used for the treatment of uveitis. By the development of molecular biology, more therapeutic agents and approaches have been applied to control ocular inflammation caused by uveitis, which are expected to have a positive influence on the uveitis treatment market. The advancements anticipated from the uveitis treatment options currently in the pipeline are sparking out serious market growth.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=uveitis-treatment-market

However, the adverse effects related to uveitis treatment medication such as watery eyes, irritation and others are the factors which are expected to hinder growth of the global uveitis treatment market. Poor primary healthcare infrastructure, lack of awareness about eye disorders, and lack of health insurance in developing countries are also obstructing the uveitis treatment market.

Some of the major competitors in the global uveitis treatment market are XOMA, pSivida Corp., Novartis, Allergan India Private Limited, Enzo Biochem Inc., AbbVie Inc., Bausch & Lomb Incorporated, Ophthalix Inc., Santen Pharmaceutical Co., Ltd., Topivert Ltd, HANALL and Regeneron Pharmaceuticals, Inc.

Read More

Protein A Resin Market to Witness the Highest Growth Globally in Coming Years

The global protein A resin market is expected to witness considerable growth during the forecast period due to the increasing research and development activities and increasing prevalence of chronic diseases. High traction for monoclonal antibodies in biopharmaceutical industry is supporting the growth of the global market. The increasing demand for monoclonal antibodies has fueled the need for high capacity commercial scale purification of monoclonal antibodies.

Protein A resins are designed for the simple and rapid purification of antibodies. Therefore, an increase in demand for monoclonal antibodies implies an increase in demand for protein A resins. The market for natural protein A resin was the larger than recombinant protein A resin market in 2015; however, recombinant protein A resin market is expected to witness the higher growth during the forecast period.

Request to Get the Sample Pages at:

Protein A, a 56 kDa surface protein, is found on the cell wall of Staphylococcus aureus bacterium. The protein has immunoglobulin-binding domains which bind to proteins, mostly immunoglobulin G (IgG). Protein A binds to the Fc region or Fab region of immunoglobulins, thus, increasingly being used for immune precipitation or antibody purification applications. Protein A ligand is used for the affinity chromatography step in commercial-scale production of monoclonal antibodies. The key factors driving the use of protein A resin for antibody purification are high antibody selectivity, increased antibody yield and excellent antibody purity, and ease of operation in large as well as small scale antibody purification.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=protein-a-resin-market

Geographically, North America accounted for the largest share in the global protein A resin market in 2015, owing to the large number of clinical trials for the monoclonal antibody based therapeutics and increasing traction for biosimilars with the recent U.S. Food and Drugs Administration in the region. The U.S. contributed largest revenue to the North American as well as global protein A resin market. The country is expected to remain the largest market for protein A resin globally during the forecast period.

The protein A resin market is expected to witness the highest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to the increasing compliance for biosimilars and shifting global interest for expanding biopharmaceutical manufacturing capacities in the emerging economies of the region.

The key players operating in the global protein A resin market are General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, Tosoh Corporation, Repligen Corporation, Novasep, Expedeon Ltd., and GenScript.

Read More